ArticleBMC rheumatology2021

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.

Christopher W Pohlmeyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.